Evidence map›Paper›PMID 22534337›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2012

The significance of endothelin in platelet-activating factor-induced fetal growth restriction.

Mark G Neerhof, Saira Khan, Sylvia Synowiec, Xiao-Wu Qu, Larry G Thaete

Open access · bronzeAbstract read
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mark G NeerhofDepartment of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA.
Saira Khan
Sylvia Synowiec
Xiao-Wu Qu
Larry G Thaete
NorthShore University HealthSystem · USUniversity of Chicago · US

Funding

Mechanisms of Vasoactive Mediator Action in FGRR01HD046968 · NICHD · NORTHSHORE UNIV HEALTHSYSTEM RES INST · PI NEERHOF, MARK G · 2004 to 2008
$1.4M
NICHD NIH HHS HD046968NICHD NIH HHS R01 HD046968
6 · The paper itself

Abstract

The significance of endothelin-1 (ET-1) in platelet-activating factor (PAF)-induced fetal growth restriction (FGR) was evaluated in timed-pregnant rats receiving intravenous carbamyl-PAF (c-PAF; 0.5, 1.0, or 2.5 µg/kg per h) or vehicle, with or without ET-1 receptor A (ET(A)) antagonist (10 or 20 mg/kg per d) for 7 days beginning on gestation day 14. Tissues were collected on day 21. Carbamyl-PAF reduced fetal weights dose dependently. Placental weights were significantly reduced but not dose dependently. ET(A) antagonism prevented FGR at the 0.5, but not the 1.0 and 2.5 µg/kg per h c-PAF doses. Correspondingly, placental, but not uterine, preproET-1 messenger RNA (mRNA) expression (determined by reverse transcription-polymerase chain reaction) was increased at 0.5 µg/kg per h but not at higher c-PAF doses. In summary, c-PAF infusion results in fetal and placental growth restriction in the rat. At low doses of c-PAF, ET-1 is central to the pathophysiology of PAF-induced FGR. At higher c-PAF doses, FGR is induced by mechanisms other than ET-1 action.

Indexed as

AnimalsEndothelin-1Endothelin A Receptor AntagonistsFemaleFetal Growth RetardationFetal WeightGene ExpressionOrgan SizePlacentaPlatelet Activating FactorPregnancyPregnancy OutcomeRatsRats, Sprague-DawleyReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionEndothelin-1Endothelin A Receptor AntagonistsPlatelet Activating FactorRNA, Messenger

Identifiers

PMID22534337
PMCPMC4051401
OpenAlexW2162779616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.